About Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals (NASDAQ:TARS) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for a variety of eye conditions. The company works on breakthrough treatments aimed at addressing significant unmet medical needs in ocular health. Among its key projects is the development of a pioneering solution for Demodex blepharitis, a common eyelid condition that Tarsus is targeting with its flagship drug candidate. This initiative highlights the company's commitment to transforming patient care in ophthalmology. Additionally, Tarsus Pharmaceuticals explores treatments for other eye diseases, underscoring its objective to become a leader in eye care solutions by delivering novel and effective therapies to patients worldwide.
Snapshot
Operations
Produtos e/ou serviços de Tarsus Pharmaceuticals Inc
- TP-03 (lotilaner ophthalmic solution, 0.25%) is designed to treat Demodex blepharitis, a common eyelid margin disease.
- Zerym (formerly TP-03) targets the elimination of Demodex mites, aiming to address the root cause of Demodex blepharitis.
- TP-04 is being developed to treat Rosacea, focusing on the inflammatory and erythematous components of the condition.
- TP-05 is an oral formulation aimed at Lyme disease prevention, targeting the reduction of Lyme disease incidence post-tick bite.
equipe executiva do Tarsus Pharmaceuticals Inc
- Dr. Bobak R. Azamian M.D.Co-Founder, President, CEO & Chairman
- Mr. Jeffrey S. Farrow CPACFO & Chief Strategy Officer
- Dr. Seshadri Neervannan Ph.D.Chief Operating Officer
- Mr. Aziz Mottiwala M.B.A.Chief Commercial Officer
- Dr. Elizabeth Yeu M.D.Chief Medical Officer
- Mr. David NakasoneHead of Investor Relations
- Dr. Bryan Wahl J.D., M.D.General Counsel & Corporate Secretary
- Ms. Adrienne KempSenior Director of Corporate Communications
- Mr. Matthew Rossen M.B.A.Vice President of Marketing
- Mr. Scott YoumansVice President of Sales